ATHX secured 3 QTDP grants totaling $730K and $140K from the Michael J. Fox Foundation for Parkinson’s Research.
- 2 are related to ATHX’s development of MultiStem(NYSE:R) for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation. MultiStem is currently being developed for the treatment of AMI, Graft vs. Host Disease (GvHD) following bone marrow transplant, inflammatory bowel disease, and stroke;
- 1 of the 3 grants was secured to advance pharmaceutical development program in obesity. ATHX is developing compounds that selectively stimulate the 5HT2c serotonin receptor in the brain, which is known to play an important role in regulating appetite.
ATHX also secured a $140K grant from the Michael J. Fox Foundation for Parkinson’s Research to advance research and development of its novel MultiStem product platform as a potential treatment for Parkinson’s disease.